Key result
Methadone use in a pediatric oncologic population was associated with an 18% occurrence rate of QTc interval prolongation.
Why the study?
Although studies have addressed the necessary frequency of QTc monitoring in adults prescribed methadone without reaching consensus, no similar research had been conducted in the pediatric population.
What is the occurrence rate of QTc interval prolongation associated with methadone use in a pediatric oncologic population?
Cohort
What is the occurrence rate of QTc interval prolongation associated with methadone use in a pediatric oncologic population?
In pediatric oncology patients on methadone, 18% developed QTc prolongation, suggesting a need for risk stratification based on baseline QTc and concurrent medications.
May warrant QTc monitoring in pediatric oncology patients on methadone; leaves open optimal frequency and protocols.
Studies have been conducted on adults prescribed with methadone to determine the necessary frequency of QTc monitoring but no consensus has been reached and no similar research has been conducted in the pediatric population. The objective of this retrospective study was to determine the occurrence rate of QTc interval prolongation associated with methadone use in a pediatric oncologic population. In total, 18% of patients developed QTc interval prolongation. These patients had longer baseline QTc intervals and were on more QTc interval-prolonging medications. Our data suggest that these variables may be able to risk stratify patients who require more frequent monitoring.
No takes yet. Share an insight, caveat, or question.
Piccininni et al. (2019) conducted a cohort in Pediatric oncology. Methadone was evaluated on Occurrence rate of QTc interval prolongation. Methadone use in a pediatric oncologic population was associated with an 18% occurrence rate of QTc interval prolongation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: